Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci

被引:48
作者
Courtney, HS
Hasty, DL
Dale, JB
机构
[1] Univ Tennessee, Vet Adm Med Ctr, Res Serv 151, Memphis, TN 38104 USA
[2] Univ Tennessee, Dept Med, Memphis, TN 38104 USA
[3] Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38104 USA
关键词
D O I
10.1128/IAI.71.9.5097-5103.2003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Serum opacity factor (SOF) is a protein expressed by Streptococcus pyogenes that opacifies mammalian serum. SOF is also a virulence factor of S. pyogenes, but it has not been previously shown to elicit a protective immune response. Herein, we report that SOF evokes bactericidal antibodies against S. pyogenes in humans, rabbits, and mice. Rabbit antiserum against purified recombinant SOF2 opsonized SOF-positive M type 2, 4, and 28 S. pyogenes in human blood but had no effect on SOF-negative M type 5 S. pyogenes. Furthermore, affinity-purified human antibodies against SOF2 also opsonized SOF-positive streptococci. A combination of antisera against M2 and SOF2 proteins was dramatically more effective in killing streptococci than either antiserum alone, indicating that antibodies against SOF2 enhance the opsonic efficiency of M protein antibodies. Mice tolerated an intravenous injection of 100 mug of SOF without overt signs of toxicity, and immunization with SOF protected mice against challenge infections with M type 2 S. pyogenes. These data indicate that SOF evokes opsonic antibodies that may protect against infections by SOF-positive serotypes of group A streptococci and suggest that different serotypes of SOF have common epitopes that may be useful vaccine candidates to protect against group A streptococcal infections.
引用
收藏
页码:5097 / 5103
页数:7
相关论文
共 48 条
[31]   Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome [J].
McCormick, JK ;
Tripp, TJ ;
Olmsted, SB ;
Matsuka, YV ;
Gahr, PJ ;
Ohlendorf, DH ;
Schlievert, PM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (04) :2306-2312
[32]   Spa contributes to the virulence of type 18 group A streptococci [J].
McLellan, DGJ ;
Chiang, EY ;
Courtney, HS ;
Hasty, DL ;
Wei, SC ;
Hu, MC ;
Walls, MA ;
Bloom, JJ ;
Dale, JB .
INFECTION AND IMMUNITY, 2001, 69 (05) :2943-2949
[33]  
Medina E, 1998, EUR J IMMUNOL, V28, P1069, DOI 10.1002/(SICI)1521-4141(199803)28:03<1069::AID-IMMU1069>3.0.CO
[34]  
2-P
[35]   Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS) [J].
Murphy, ML ;
Pichichero, ME .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2002, 156 (04) :356-361
[36]   Epidemiology of invasive group A Streptococcus disease in the United States, 1995-1999 [J].
O'Brien, KL ;
Beall, B ;
Barrett, NL ;
Cieslak, PR ;
Reingold, A ;
Farley, MM ;
Danila, R ;
Zell, ER ;
Facklam, R ;
Schwartz, B ;
Schuchat, A .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (03) :268-276
[37]   Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope [J].
Olive, C ;
Clair, T ;
Yarwood, P ;
Good, MR .
VACCINE, 2002, 20 (21-22) :2816-2825
[38]   A lipid core peptide construct containing a conserved region determinant of the group a streptococcal M protein elicits heterologous opsonic antibodies [J].
Olive, C ;
Batzloff, MR ;
Horváth, A ;
Wong, A ;
Clair, T ;
Yarwood, P ;
Toth, I ;
Good, MF .
INFECTION AND IMMUNITY, 2002, 70 (05) :2734-2738
[39]  
PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729
[40]   DNA-SEQUENCE OF THE SERUM OPACITY FACTOR OF GROUP-A STREPTOCOCCI - IDENTIFICATION OF A FIBRONECTIN-BINDING REPEAT DOMAIN [J].
RAKONJAC, JV ;
ROBBINS, JC ;
FISCHETTI, VA .
INFECTION AND IMMUNITY, 1995, 63 (02) :622-631